|
KMID : 1001020120100010001
|
|
Journal of Urologic Oncology
2012 Volume.10 No. 1 p.1 ~ p.5
|
|
|
What is the High Risk Prostate Cancer?
|
|
Park Seung-Chol
|
|
|
Abstract
|
|
|
|
An accurate estimate of overall and disease-specific survival is critical for an informed discussion of treatment options among men with newly diagnosed prostate cancer. The risk of relapse following therapy has been estimated by using multiple definitions ranging from a single parameter, including clinical stage, prostate specific antigen, and Gleason score, to a combination of variables to scoring system or nomogram definition. The most commonly accepted definition was proposed by D’Amico and defines high risk prostate cancer as prostate specific antigen more than 20ng/ml or Gleason score 8-10 or clinical stage of at least T2c. High risk prostate cancer had shown low disease specific survival and overall survival. Long-term survival depends, in part, on risks posed by the tumors and risks posed by existing comorbidity. Therefore more accurate stratification of the individual patient’s risk for progression and likelihood of response to treatment are required. And the new biomarkers are needed to predict survival. This article reviewed the definition of high risk prostate cancer and natural history of high risk prostate cancer.
|
|
|
KEYWORD
|
|
|
Prostate cancer, Prognosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|